The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Pulmonary hypertension (PH) is a life-threatening cardiovascular disease characterized by pathological elevation of mean pulmonary arterial pressure (mPAP) >/= 25 mmHg at rest. mPAP < 20 mmHg is defined as normal, values in the range between 21-24 mmHg are described as "borderline PH" diagnosed by right heart catheterization. Based on the etiology, PH is assigned to 5 groups (WHO, Data Point, 2008), whereas classification of disease is an important prognostic and therapy-deciding criterion.

Aim of this explorative study is to 1. analyse PH-associated blood flow characteristics in the heart and the surrounding great vessels with respect to the 5 groups of PH, and 2. investigate the hemodynamic state of "borderline PH" compared to normal mPAP and manifest PH by non-contrast CMR.

patients with suspected or known PH scheduled for routine right-heart catheterization,

ability to give informed consent.

Exclusion Criteria:

General MR exclusion criteria eg. patients with metal devices or other magnetic material in or on the subjects body which will be hazardous for MR investigation (e.g. heart pace-maker, brain aneurysm clip, nerve stimulators, electrodes, penile implants, coloured contact lenses, patch to deliver medications through the skin, any metal implants as rods, joints, plates, pins, screws, nails or clips, embolization coil, or any metal fragments or shrapnel in the body),

patients with tendency toward claustrophobia,

hemodynamically unstable patients,

pregnancy.

Sex/Gender

Sexes Eligible for Study:

All

Ages

18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Contacts ICMJE

Contact information is only displayed when the study is recruiting subjects

Listed Location Countries ICMJE

Austria

Removed Location Countries

Administrative Information

NCT Number ICMJE

NCT01725763

Other Study ID Numbers ICMJE

CMR-12-PH

Has Data Monitoring Committee

Yes

U.S. FDA-regulated Product

Not Provided

IPD Sharing Statement

Not Provided

Responsible Party

Ursula Reiter, Medical University of Graz

Study Sponsor ICMJE

Medical University of Graz

Collaborators ICMJE

Not Provided

Investigators ICMJE

Principal Investigator:

Ursula Reiter, PhD

Medical Unitersity Graz, Department of Radiology, Division of General Radiology

Principal Investigator:

Michael Fuchsjäger, Prof. Dr.

Medical Unitersity Graz, Department of Radiology, Division of General Radiology